TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04933955

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vital pulp therapy
Description: pulpotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vital pulp therapy
Description: pulpotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vital pulp therapy
Description: pulpotomy
Study: NCT05556863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELA026
Description: Single dose of ELA026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELA026
Description: Multiple doses of ELA026
Study: NCT04791228

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance-Guided High Intensity Focused Ultrasound
Description: Magnetic resonance (MR)-guided high intensity focused ultrasound (HIFU) provides precise and controlled delivery of heat by focusing ultrasound energy inside a lesion using an external applicator without the need for a scalpel or needle.~Additional therapeutic advantages of this modality include its range of bioeffects, including both high temperature tumor ablation via coagulative necrosis, and effects of lower temperature, mild hyperthermia that can help to enhance local drug delivery to tumors. Both tumor ablation and hyperthermia may be employed to potentiate the effects of chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyso-thermosensitive Liposomal Doxorubicin
Description: LTLD combines doxorubicin with lyso-thermosensitive liposomes that can selectively deliver drug to tumors and when exposed to temperatures greater than 40°C, rapidly and locally releases doxorubicin in high concentrations from systemically administered LTLD.~If combined with hyperthermia, doxorubicin will be released in the heated tumor margins and in any areas within the tumor that were not completely ablated and increase the likelihood of complete tumor necrosis. LTLD will extend tumor cell death to the hyperthermic regions in the peri-ablation zones and minimize the possibility of incomplete ablation or tumor recurrence.
Study: NCT04557462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNP023
Description: Capsule 200 mg (b.i.d.) taken orally twice a day
Study: NCT05586542

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: DERMASEAL
Description: a novel skin substitute formulated as planar, thin film

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma Film
Description: a planar, thin film made from human plasma

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: standard procedures for managing diabetic foot ulcers including debridement of unhealthy tissue and maintenance of a moist wound environment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: standard procedures for managing diabetic foot ulcers including debridement of unhealthy tissue and maintenance of a moist wound environment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: standard procedures for managing diabetic foot ulcers including debridement of unhealthy tissue and maintenance of a moist wound environment
Study: NCT06512155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Start taking 75mg bid of pregabalin two days before surgery, and take 150mg bid of pregabalin from one day before surgery to three days after surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: Take zolpidem 10mg qn from two days before surgery to three days after surgery
Study: NCT05160051

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI-46 PET Scan
Description: 68Ga-FAPI-46 is a radiotracer that binds with high affinity to Fibroblast Activating Protein (FAP). FAP is physiologically expressed in many tissues during embryonic development, but in adults it is expressed only in the context of wound healing, fibrotic processes, and the stroma of many malignancies. Therefore, the study seeks to validate if 68Ga-FAPI-46 PET could be established as a diagnositc tool to detect solid tumors.
Study: NCT05099848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Procedure:~1. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally on the 1st day 30minutes after meals, once a day, for continuous medication.~2. On the 2nd day of treatment, intravenous infusion of Camrelizumab 200mg every 3 weeks.~3. On the 3rd to 4th day of treatment, HAIC was conducted through a catheter intubated into the tumor feeding artery under DSA guidance with the following chemotherapeutic drugs (mFOLFOX, oxaliplatin 85 mg/m2 in 0-2 hours, folinic acid 400 mg/m2 in 2-3 hours, 5-FU 2500 mg/m2 46 hours) pumped into the tumor artery. The HAIC is repeated every 3 weeks. The cumulative maximum sessions of HAIC is up to 8 times.~The cumulative maximum drug use period is up to 8 cycles. Patient will be administratied radical resection if possible during treatment. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear.
Study: NCT06201962

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Massage applications will be performed for 15 minutes every morning and evening for two days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot Reflexology
Description: In the reflexology group, the researcher will hold the baby's foot with his left hand and gently massage each foot with the thumb of his right hand for 15 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Newborns will receive routine medical treatment and nursing care and will not undergo any procedures.
Study: NCT04675476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Prompt & Patient Outreach and Education
Description: To target lack of provider-prompted discussion about lung screening, an electronic medical record (EMR) message will be sent to primary care providers prior to scheduled visits with screening-eligible patients to notify them of the patient's eligibility and to encourage discussion of the benefits and limitations of the test. To target patient-level knowledge about lung screening, an outreach specialist will educate screening-eligible patients about the benefits and limitations of the test prior to their visit.
Study: NCT06090318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1680mg administered every 4 weeks
Study: NCT05854472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: smartphone based application use
Description: A smartphone application content will be developed to facilitate the use of immunosuppressive drugs by individuals with liver transplantation and to provide guidance to patients. The effect of smartphone application usage on immunosuppressive drug compliance, anxiety and quality of life in liver transplant patients will be evaluated.
Study: NCT05403580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05794269

Intervention type: OTHER
Intervention: TQoR-15 questionnaire
Description: The TQoR-15 questionnaire (Turkish version) consists of 15 questions concerning five domains (the patient's feelings, comfort, pain, dependence on the health care team and psychological well-being). Two to three minutes are required to complete all the questions. If the patient is not able to read the questionnaire himself, a third person can ask the patient the questions orally. Each item is scored from 0 to 10 and the total score is the sum of the score obtained for each item, i.e. a score from 0 to 150.
Study: NCT06296758

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional anesthesia
Description: ultrasound-guided suprainguinal fascia iliaca block with 40ml of ropivacaine local or ultrasound-guided femoral nerve block with 20ml of ropivacaine local anesthetic
Study: NCT05516485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment
Description: Undergo grading and recording of tumor consistency/stiffness

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Elastography
Description: Undergo MRE
Study: NCT05903469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implicit Attitude Test
Description: The IAT (Implicit Attitude Test) is a method of indirectly measuring the relative strength of associations between different concepts stored in memory based on reaction times on computer. The general idea behind this measure is that an individual will be much faster to categorize an object into a predetermined category, if this categorization is consistent with their own way of processing information.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implicit Attitude Test
Description: The IAT (Implicit Attitude Test) is a method of indirectly measuring the relative strength of associations between different concepts stored in memory based on reaction times on computer. The general idea behind this measure is that an individual will be much faster to categorize an object into a predetermined category, if this categorization is consistent with their own way of processing information.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implicit Attitude Test
Description: The IAT (Implicit Attitude Test) is a method of indirectly measuring the relative strength of associations between different concepts stored in memory based on reaction times on computer. The general idea behind this measure is that an individual will be much faster to categorize an object into a predetermined category, if this categorization is consistent with their own way of processing information.
Study: NCT05406479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BE-PEP (Bedaquiline)
Description: Single dose of Bedaquiline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SDR-PEP
Description: Single dose of Rifampicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BE-PEP (Rifampicine)
Description: Single dose of Rifampicin
Study: NCT05185037

Intervention type: DEVICE
Intervention: Philips IntelliVue X3 patient monitor with investigational NIBP measurement algorithm (measured once per 3 minutes)
Description: The purpose of this study is to compare measurements of NIBP taken by the study device and measurements taken by the current FDA-approved algorithm included in Rev. N.0 software for the IntelliVue patient monitors during motion artifact in patients undergoing caesarian section deliveries under epidural anesthesia
Study: NCT06427668

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPG302
Description: synthetic small molecule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPG302
Description: synthetic small molecule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05969093

Intervention type: DIAGNOSTIC_TEST
Intervention: Tinel's Sign performed at different wrist positions
Description: Participants will undergo the Tinel's Sign at different wrist positions while EMG activity and NCV are recorded to investigate the effect of wrist position on median nerve activity.
Study: NCT04709146

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Audio-Vestibular evaluation
Description: Diagnostic evulation with audiometry, Tympanography, SVV, VHIT, VNG.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Audio-Vestibular evaluation
Description: Diagnostic evulation with audiometry, Tympanography, SVV, VHIT, VNG.
Study: NCT06211686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein powder and Resistance exercise
Description: 1. Protein powder supplementation 25-30 g/day~2. Resistance exercise 2 time/week
Study: NCT05918120

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Sleep Apnea Test
Description: Use of a home sleep apnea test that records respiratory effort, pulse, oxygen saturation and nasal flow, and reports apneas, hypopneas, flow limitation, snoring and blood oxygen saturation in order to detect obstructive sleep apnea.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: In-laboratory polysomnography
Description: Level 1 in-laboratory polysomnography for the detection of obstructive sleep apnea.
Study: NCT05878639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 bottles of Lactulose oral solution
Description: Patients will take lactulose for bowel preparation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3L-polyethylene glycol
Description: Patients will take 3L-polyethylene glycol for bowel preparation.
Study: NCT05870800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2
Description: Enrolled Participant will receive 4 cycles of neoadjuvant Atezolizumab (Tecentriq) followed by CAPEOX chemotherapy prior to surgery. Each cycle is every 3 weeks. (12 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2
Description: After Surgery, if patients are still considered at high risk (per treating investigator) subjects will be eligible to receive adjuvant chemotherapy with mFOLFOX6 Q2 weeks x 6 cycles (12 weeks) or CAPEOX Q3 weeks x 4 cycles (12 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2
Description: After Surgery, if patients are still considered at high risk (per treating investigator) subjects will be eligible to receive adjuvant chemotherapy with mFOLFOX6 Q2 weeks x 6 cycles (12 weeks) or CAPEOX Q3 weeks x 4 cycles (12 weeks)
Study: NCT04542343

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Change in knowledge, motivation, skills, resources
Description: Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce COVID-19 related risk and challenges.
Study: NCT06495775

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: quickfact
Description: fecal sampling
Study: NCT05278273

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeurotrackerX
Description: At-home participants loaned the necessary equipment (e.g., 3D-glasses, computer equipment) from the research facilities and engaged in 10 training sessions over five weeks (2x per week). Participant recruitment, retention, adherence and experience were used as markers of feasibility. For program validation, twenty participants above 50 years old, who had previously completed at least eight sessions of the in-lab 3D-MOT program, were randomly selected as the control group.
Study: NCT05194774

Intervention type: PROCEDURE
Intervention: Greater Trochanter epiphysiodesis
Description: epiphysiodesis by cortical screw and washer
Study: NCT06333925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Frequency Repetitive Transcranial Magnetic Stimulation (HF rTMS)
Description: 10 Hz rTMS over the right dorsal lateral prefrontal cortex (dlPFC)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation (sham- rTMS)
Description: inactive rTMS over the right dorsolateral prefrontal cortex (dlPFC)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring
Description: Cognitive restructuring is a cognitive behavioral intervention through which participants learn how to think differently about misophonic sound triggers in order to feel less emotional arousal.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Restructuring
Description: Cognitive restructuring is a cognitive behavioral intervention through which participants learn how to think differently about misophonic sound triggers in order to feel less emotional arousal.
Study: NCT03833206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDC-1421 Capsule
Description: PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDC-1421 Capsule
Description: PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
Study: NCT05472233

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture removal after Coronally Positioned Flap
Description: Sutures are removed after different healing period post coronally positioned flap surgery, this latter is a procedure that aims at surgically advancing the gingiva in order to cover dehiscences of the soft tissues uncovering dental roots.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suture removal after Coronally Positioned Flap
Description: Sutures are removed after different healing period post coronally positioned flap surgery, this latter is a procedure that aims at surgically advancing the gingiva in order to cover dehiscences of the soft tissues uncovering dental roots.
Study: NCT04827212

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Companion
Description: Companion integrates wearable sensing with the smartphone to develop a behavior-aware, virtual system that uses a human-in-the-loop approach to enable meaningful two-way communication. Companion builds rich models of typical behavior using sensors and context sensitive ecological momentary assessment to deliver intervention components and behavior change strategies using socially engaging, contextually salient, and tailored text-message conversations in near-real-time.
Study: NCT05118737

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colchicine
Description: colchicine to be used among COVID-19 patients admitted to HMGH, CH, and CDC and already received tocilizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: colchicine to be used among COVID-19 patients admitted to HMGH, CH, and CDC and already received tocilizumab
Study: NCT06446843

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: (Arthrocentesis following i-PRF +HA)
Description: Intra-articular I-PRF with HA will be injected in the joint,1 ml of I-PRF will be injected inside the joint, Then from 25mg/ml of HA , 1ml will be injected into the superior joint space

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: (Arthrocentesis following i-PRF +HA)
Description: Intra-articular I-PRF with HA will be injected in the joint,1 ml of I-PRF will be injected inside the joint, Then from 25mg/ml of HA , 1ml will be injected into the superior joint space

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: (Arthrocentesis following i-PRF +HA)
Description: Intra-articular I-PRF with HA will be injected in the joint,1 ml of I-PRF will be injected inside the joint, Then from 25mg/ml of HA , 1ml will be injected into the superior joint space
Study: NCT05510843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THB001
Description: 100 mg capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THB001
Description: 100 mg capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THB001
Description: 100 mg capsules for oral administration
Study: NCT05795582

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POPMETRE® (Axelife , France)
Description: Measurement with 2 devices
Study: NCT06385808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTBF regimen
Description: The subjects will be treated with mitoxantrone hydrochloride liposome combined with thiotepa, busulfan and fludarabine as conditioning regimen prior to allo-HSCT.~Mitoxantrone hydrochloride liposome 24mg/m\^2 ivgtt d-7; Ctepide 5mg/kg ivgtt d-6\~-5; Busulfan 0.8mg/kg q6h ivgtt d-4\~-2; Fludarabine 50mg/m\^2 ivgtt d-4\~-2.
Study: NCT06147895

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVI-HBV-002
Description: Investigational Product

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVI-HBV-002
Description: Investigational Product
Study: NCT05290350

Intervention type: OTHER
Intervention: OSA
Description: EXPOSURE TO OBSTRUCTIVE SLEEP APNEA
Study: NCT05022680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mhealth
Description: the peer-led intervention with mHealth technology (an application (APP) and Sports bracelet)
Study: NCT06242626

Intervention type: OTHER
Intervention: observation
Description: analysis of clinical, laboratory and haemodynamics parameters

Intervention type: OTHER
Intervention: observation
Description: analysis of clinical, laboratory and haemodynamics parameters
Study: NCT06074055

Intervention type: OTHER
Group type: OTHER
Intervention: FET Protocol
Description: Participants are randomized to either another programmed FET Protocol vs. a modified natural FET protocol

Intervention type: OTHER
Group type: OTHER
Intervention: FET Protocol
Description: Participants are randomized to either another programmed FET Protocol vs. a modified natural FET protocol
Study: NCT05199597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.01% atropine
Description: 0.01%, room temp, Lab A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.05% atropine
Description: 0.05%, room temp, Lab A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.05% atropine
Description: 0.05%, refrigerated, Lab A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.05% atropine
Description: 0.05%, room temperature, Lab B
Study: NCT05787717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parental presence
Description: The parent is encouraged to stay close to their child and are given ample room on one side of the OR table for this purpose
Study: NCT06314113

Intervention type: DIETARY_SUPPLEMENT
Intervention: Epigallocatechin Gallate
Description: Oral treatment with Epigallocatechin Gallate 200 mg per day
Study: NCT06578494

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound-guided peripheral intravenous catheter insertion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound-guided peripheral intravenous catheter insertion
Study: NCT06576778

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PROVSIONALIZATION
Description: glass fiber composite as a temporary framework followed by PEKKTON definitive framework.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PROVSIONALIZATION
Description: glass fiber composite as a temporary framework followed by PEKKTON definitive framework.